跳至主要内容
临床试验/NCT05293405
NCT05293405招募中不适用

Neuroinflammatory Imaging Using TSPO PET Tracer in Paients With Autoimmune Encephalomyelitis

Ruijin Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年12月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
TSPO expression level

研究概览

简要总结

Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal surface proteins, synaptic receptors and intracellular antigens. MRI, as a current first-line imaging tool of CNS inflammation, is difficult to diagnose them because the majority of patients have normal MRI images, and only a few may show local signal or structural abnormalities (including inflammation, edema, or atrophy). The 18 kDa translocator protein (TSPO) expression in the CNS is upregulated in response to microglia activation. DPA-714 is high affinity for binding to TSPO, making 18F-labeled DPA-714 (18F-DPA-714) PET a very promising diagnostic imaging tool for neuroinflammation in patients with autoimmune encephalomyelitis.This study aims to explore the value of 18F-DPA-714 PET in the early diagnosis, therapeutic assessment and prognosis in patients with autoimmune encephalomyelitis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
16 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Experimental group:
  • •Inclusion criteria:
  • •Patients with onset for less than 2 years
  • •Serum autoantibody positive
  • •cognitive impairment or movement disorder diagnosed by two or more certified specialists.

排除标准

  • •Patients who do not meet the clinical、laboratory and imaging criteria of immune-related cognitive and movement disorders
  • •Medical history of surgery, trauma, stroke, tumor in brain or spine cord
  • •Alcoholism or drug dependence (addiction)
  • •Patients with pregnancy
  • •Healthy Volunteers group:
  • •Inclusion criteria:
  • •able to understand the purpose of clinical research and test plan
  • •In the brain and spine cord MR assessment, it is judged as "normal"
  • •Exclusion criteria:
  • •Any major mental illness; history of schizophrenia or schizoaffective disorder
  • •Any important neurological disease, such as cerebrovascular disease, inflammation or infectious disease, demyelinating disease, neurodegenerative disease, trauma in brain or spine cord
  • •History of alcohol or drug abuse/dependence
  • •Medical history of cardiac and lung disease, tumors, blood disease, poorly controlled chronic diseases
  • •Patients with pregnancy

研究组 & 干预措施

Patients Group

Experimental

干预措施: 18F-DPA-714 PET (Diagnostic Test)

Healthy Volunteers Group

Sham Comparator

干预措施: 18F-DPA-714 PET (Diagnostic Test)

结局指标

主要结局

TSPO expression level

时间窗: 12 months after baseline

quantitatively assessing the level of neuroinflammation in all brain regions or spinal cord

TSPO expression level

时间窗: Baseline

quantitatively assessing the level of neuroinflammation in all brain regions or spinal cord

TSPO expression level

时间窗: 3 months after baseline

quantitatively assessing the level of neuroinflammation in all brain regions or spinal cord

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验